Assessment of Abuse Potential of Rapastinel in Humans
Brief Summary
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.
Condition or Disease
- Human Abuse Potential
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Completed |
| Study results: | No Results Available |
| Age: | 18 Years to 55 Years (Adult) |
| Enrollment: | 72 () |
| Funded by: | Industry |
Masking |
|
Clinical Trial Dates
| Start date: | Nov 01, 2018 | |
|---|---|---|
| Primary Completion: | Mar 24, 2019 | |
| Completion Date: | Mar 29, 2019 | |
| Study First Posted: | Jan 10, 2019 | |
| Results First Posted: | Aug 31, 2020 | |
| Last Updated: | May 16, 2019 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 18 |
| Maximum Age: | 55 |
More Details
| NCT Number: | NCT03799900 |
|---|---|
| Other IDs: | RAP-PK-12 |
| Study URL: | https://ClinicalTrials.gov/show/NCT03799900 |
Last updated: Jan 27, 2021